Research · Sep 3, 2026
[BDX] Becton Dickinson Thesis 2026: BD 2025 Strategy Tests Medical Device Portfolio Simplification
Becton, Dickinson and Company FY2025 revenue ~$20.5-21B (+2-4%) with adj. EPS ~$13.50-14.00 reflecting continued portfolio simplification under BD 2025 strategy + selected M&A integration (Bard 2017 + Edwards Lifesciences Critical Care announced February 2025) + selected hospital capex stabilization + selected operational discipline. Large global medical device + diagnostics company; founded 1897 by Maxwell Becton + Fairleigh Dickinson in New Jersey. 3 segments: BD Medical ~49% ($10B — Medication Delivery Solutions IV catheters/infusion + Medication Management Pyxis automated dispensing + Diabetes Care + Pharmaceutical Systems) + BD Life Sciences ~24% ($5B — Integrated Diagnostic Solutions microbiology/molecular + Biosciences research instruments) + BD Interventional ~24% ($5B — post-2017 CR Bard $24B acquisition; Surgery + Peripheral Intervention + Urology and Critical Care). ~75K+ employees globally + ~190+ country presence. CEO Tom Polen since January 28, 2020 (succeeded Vincent Forlenza CEO 2011-2020 who became Executive Chair; Polen ex-BD President + COO 2017-2020; ~30-year BD career). Polen tenure executed continued BD 2025 strategy (portfolio simplification + M&A pipeline + selected mid-single-digit revenue growth target) + Edwards Critical Care $4.2B all-cash acquisition announced February 6, 2025 (~$1B revenue critical care monitoring portfolio; closing expected FY2025 H2 / FY2026 H1; transformational addition to BD Interventional segment) + selected diagnostics divestitures + selected operational excellence. Capital return: dividend $4.00-4.16/share (52 consecutive year increases — Dividend King) + buybacks $0.5-1B; net debt $15-16B; Baa2/BBB+ investment grade. FY2026 thesis: BD 2025 strategy + Edwards Critical Care + hospital capex + capital return. Risks: hospital capex cycle, China cycle, competitive intensity from Medtronic + Boston Scientific.